2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2361

the Role of CD146 in the Therapeutic Potential of Mesenchymal Stem Cells in Favor of CD146⁺ Cells for Experimental Arthritis
Abstract Number: 2358

The Role of Dendritic Cells during Inflammatory Arthritis
Abstract Number: 2741

The Role of Fli1 in Lupus T Cell Function and Nephritis
Abstract Number: 2610

The Role of IL-20 in the Pathogenesis of Ankylosing Spondylitis with Peripheral Joint Involvement
Abstract Number: 1861

The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis
Abstract Number: 2447

The Role of TET3-Mediated DNA Demethylation By Pro-Inflammatory Cytokines in Rheumatoid Arthritis
Abstract Number: 1971

The Role of the Proinflammatory Mediator High-Mobility Group Box Protein 1 (HMGB1) in Anti-Collagen-Antibody-Induced Arthritis Is Dependent on Vascular Endothelial Growth Factor (VEGF)
Abstract Number: 1210

The Role of the Transcription Factor cAMP Responsive Element Binding Protein 1 in Lipopolysaccharide-Induced Tolerance
Abstract Number: 516

The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Abstract Number: 873

The Second Messenger, Cyclic GMP-AMP Dinucleotide (cGAMP) and the Enzyme, Cyclic GMP-AMP Synthase (cGAS), Are Expressed in Systemic Lupus Erythematosus
Abstract Number: 2675

The Selective Loss of SLAMF4⁺ CD8⁺ T Cells Contributes to the Decreased Cytotoxic Capacity Observed in Systemic Lupus Erythematosus
Abstract Number: 910

The Selective Sphingosine-1- Phosphate Receptor 1/5 Modulator Siponimod (BAF312) Shows Beneficial Effects in Patients with Active, Treatment Refractory Polymyositis and Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind, Randomized Trial
Abstract Number: 2536

The Sjögren’s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy
Abstract Number: 454

The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis
Abstract Number: 1567

The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].